Core Insights - AB Science has identified a plasma biomarker that indicates the activity of masitinib in treating Amyotrophic Lateral Sclerosis (ALS) and can identify patients with pro-inflammatory microglia, which are targeted by masitinib [1][2] - This biomarker is also applicable to progressive forms of Multiple Sclerosis (MS) and Alzheimer's disease, potentially enhancing treatment response identification and registration chances in neurodegenerative diseases [1][2] Biomarker Characteristics - The biomarker is blood-based, easy to collect, and can be accurately evaluated using ELISA [4] - It is produced by pro-inflammatory microglia, activates microglia and astrocytes, and contributes to a neuroinflammation feedback loop [4] - It is predictive of survival in ALS, potentially explaining why masitinib could extend survival in specific patients [4] Clinical Development - The biomarker will be introduced in the phase 3 program of masitinib for ALS, progressive MS, and Alzheimer's disease to validate its mechanism of action and clinical relevance [3] - Once validated, it could facilitate patient registration by determining the best responders to treatment and serve as a surrogate endpoint of efficacy [3] Regulatory Context - The FDA encourages the incorporation of exploratory biomarkers in all phases of ALS drug development, which may lead to discussions on surrogate endpoints for accelerated approval [3]

Core Insights - Stonegate Capital Partners has initiated coverage on AB Science S.A., focusing on its late-stage biotech asset, masitinib, which is an oral, selective tyrosine kinase inhibitor aimed at modulating maladaptive neuroinflammation [1] Company Overview - AB Science is advancing masitinib as an add-on therapy for conditions such as ALS (Amyotrophic Lateral Sclerosis), progressive MS (Multiple Sclerosis), and Alzheimer's Disease (AD) [1] - The company is also developing AB8939 for Acute Myeloid Leukemia (AML), indicating a diverse pipeline [1] Clinical Development - The ALS program is supported by prior Phase 2b/3 data, enhancing confidence in its efficacy [6] - For progressive MS, a Phase 3 trial has been authorized in the US and 12 EU countries, with approximately 94 sites initiating the study [6] - Financing for these trials is supported by grants, indicating a solid financial backing for ongoing research [6]

Core Viewpoint - AB Science has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering the use of masitinib in treating metastatic castrate-resistant prostate cancer (mCRPC), strengthening its intellectual property position until 2042, in addition to existing coverage in Europe [1][2]. Intellectual Property Position - The new US patent will provide IP protection for masitinib in mCRPC until May 2042, following the confirmation of patentability requirements by the USPTO [2]. - This patent complements the existing European patent (EP4175639) [2]. Clinical Context and Treatment Positioning - Masitinib is positioned as a treatment for mCRPC patients eligible for chemotherapy, specifically in combination with docetaxel, following hormone therapy [5]. - It is one of the few drugs that has shown positive data on progression-free survival (PFS) when combined with docetaxel in this patient population [5]. Study Results - Key results from study AB12003 indicate that masitinib (6.0 mg/kg/day) plus docetaxel significantly improved PFS in mCRPC patients with baseline alkaline phosphatase levels ≤250 IU/L, showing a 21% reduction in the risk of progression compared to control [7]. - The study demonstrated significant improvements in 12-, 18-, and 24-month PFS rates for masitinib plus docetaxel relative to control, with rates increasing by 1.6-fold, 1.9-fold, and 1.9-fold respectively [7]. Unmet Medical Need - Metastatic prostate cancer represents a significant unmet medical need, with a 5-year survival rate of approximately 32% [8]. - The global incidence of prostate cancer is high, with 1.5 million new cases and 397,000 deaths annually, and around 50,000 patients in the EU and 70,000 in the USA are eligible for chemotherapy due to mCRPC [9].

Core Viewpoint - AB Science has received a Japanese patent for the use of masitinib in treating progressive forms of multiple sclerosis (MS), providing intellectual property protection until February 2041, marking Japan as the first country to grant this patent [1][2]. Group 1: Patent and Market Position - The patent granted in Japan (JP 7788154) is the first for masitinib in progressive MS, following a similar successful patent strategy for amyotrophic lateral sclerosis (ALS) [2]. - AB Science is optimistic about obtaining global patent protection for masitinib in progressive MS, similar to its ALS patent [2]. - The company is pursuing a secondary medical use patent strategy for various indications, including progressive MS, Alzheimer's Disease, and prostate cancer, with protection extending into the 2040s [3]. Group 2: Clinical Studies and Efficacy - Masitinib has shown a unique and competitive positioning in treating both primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (nSPMS) [3]. - The development of masitinib is supported by positive results from phase 2b/3 study (AB07002) and the confirmatory phase 3 MAXIMS study (AB20009), with the former showing a statistically significant reduction in disability progression [3][4]. - In study AB07002, masitinib 4.5 mg/kg/day reduced the risk of first disability progression by 42% and improved manual dexterity, with a significant reduction in the risk of reaching an EDSS score of 7.0 [3][4]. Group 3: Safety Profile - The safety profile of masitinib is well characterized, based on data from over 4,300 patients, with no increased risk of infection observed [5][6]. - Masitinib is the first and only drug in phase 3 trials designed to target both mast cells and microglia, which is an effective strategy for treating progressive forms of MS [8]. - Unlike BTK inhibitors, masitinib does not target B-cells, which are associated with increased infection risk, making it a safer option for patients with progressive MS [6][8]. Group 4: Medical Need and Market Context - There is a significant medical need for treatments targeting progressive forms of MS, which affect over 100,000 people in France alone, with no definitive treatment currently available [10]. - Progressive forms of MS account for approximately 50% of all MS cases, highlighting the unmet medical need in this patient population [13]. - Recent failures of BTK inhibitors in clinical trials for MS further emphasize the demand for effective therapies like masitinib [14].

Core Viewpoint - AB Science has received a formal patent grant in the United States for masitinib in the treatment of sickle cell disease, providing intellectual property protection until November 2040, which strengthens its portfolio for a treatment addressing a significant unmet medical need [1][2]. Group 1: Masitinib and Sickle Cell Disease - Masitinib is being developed to treat the most severe forms of sickle cell disease (SCD), which account for approximately 65% of cases, and poses a major public health challenge [1][2]. - Current treatment options for SCD, such as hydroxyurea and red blood cell transfusions, do not fully address the complications, indicating a high unmet medical need for effective therapies [6][10]. - The disease affects millions globally, with around 300,000 children born with SCD each year, and the number is projected to reach 400,000 by 2050 [4]. Group 2: Clinical Development and Funding - The clinical development of masitinib in SCD is part of the SICKMAST collaborative program, which is fully funded with 9.2 million euros, aiming to demonstrate efficacy in a phase 2 clinical trial [2][3]. - The phase 2 study is designed in two steps, focusing on identifying biomarkers and demonstrating the efficacy of masitinib in treating acute and chronic complications of SCD [3]. Group 3: Mechanism of Action - Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, such as vaso-occlusive crises and acute chest syndrome [2][8]. - Preclinical studies have shown that masitinib provides a survival benefit in SCD mouse models, preventing vaso-occlusive crises and acute lung injury [2][8]. Group 4: Current Treatment Landscape - Existing treatments like allogeneic stem cell transplantation and gene therapy are limited to a minority of patients due to toxicity and high costs, highlighting the need for new therapeutic approaches [6][10]. - Anti-P-selectin antibodies and other previously considered treatments have failed to confirm efficacy, further emphasizing the demand for innovative solutions in managing SCD [7][10].

Core Viewpoint - AB Science SA has announced the initiation of coverage of its stock by Maxim Group, with a target price set at €4.00 per share [1][2]. Group 1: Coverage Initiation - Maxim Group has published a study titled "Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS," recommending a buy rating for AB Science's stock [2][3]. - The study emphasizes the promising benefits of masitinib across three neurodegenerative diseases, validating the mast cell inhibition approach [3]. Group 2: Financial Analyst Consensus - This initiation of coverage by Maxim Group completes the coverage of AB Science's stock, adding to the consensus from other financial analysts including Chardan, In Extenso Finance, and DNA Finance [4]. Group 3: Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [5]. - The company's lead compound, masitinib, is already registered for veterinary medicine and is being developed for human medicine in various fields including oncology and neurological diseases [6].

Core Viewpoint - AB Science has published a new article identifying AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia (AML) and potentially other cancers, highlighting its dual mechanism of action and effectiveness against multidrug resistance [1][2]. Group 1: Drug Candidate Characteristics - AB8939 is characterized as a novel synthetic microtubule destabilizer and ALDH inhibitor, showing potential for treating high-risk AML, particularly in cases with complex karyotypes, MECOM rearrangements, and TP53 mutations [3][4]. - The drug exhibits dual action against proliferating tumor cells through tubulin disruption and quiescent, resistant stem cells via ALDH inhibition, making it a unique therapeutic agent [3][4]. Group 2: Mechanism of Action - AB8939 acts as a microtubule-targeting agent by binding to the colchicine-binding site on β-tubulin, disrupting the microtubule network, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis [4]. - It is a potent inhibitor of ALDH1 and ALDH2 enzymes, which are often overexpressed in tumors and associated with cancer stem cells, tumor progression, and resistance to therapy [4]. Group 3: Efficacy and Resistance - AB8939 demonstrates strong antiproliferative activity against various human cancer cell lines, particularly hematopoietic cancers, with IC₅₀ values in the nanomolar range [4]. - The drug can overcome major mechanisms of drug resistance, including P-glycoprotein (P-gp) efflux and high β3-tubulin expression, retaining efficacy in resistant AML patient blasts [4][5]. Group 4: Clinical Trials - AB8939 is currently being evaluated in a Phase I/II clinical trial (AB18001) for patients with refractory and relapsed AML, with regulatory approval received to initiate the third stage of the study [5][6]. - The first two stages of the trial involved 28 and 13 patients, respectively, determining the maximum tolerated dose (MTD) of 21.3 mg/m² after both three and fourteen consecutive days of treatment [6]. Group 5: Intellectual Property and Regulatory Status - AB8939 is protected by intellectual property rights until 2036 or even 2044, with a patent covering its composition and use in AML treatment granted in multiple countries [7][8][9]. - The drug has received orphan drug designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), granting it marketing exclusivity for 10 years in Europe and 7 years in the US [10].

Core Viewpoint - AB Science has announced the identification and characterization of a novel small synthetic molecule, AB8939, as a promising drug candidate for treating refractory acute myeloid leukemia (AML) and potentially other cancers [1] Group 1: Drug Candidate Characteristics - AB8939 is identified as a powerful compound with a dual mechanism of action, disrupting microtubule formation and inhibiting ALDH enzymes, which are linked to therapy resistance and the survival of leukemic stem cells [2][3] - The drug shows potential for treating high-risk AML cases, particularly those with complex karyotypes, MECOM rearrangements, and TP53 mutations [3] - AB8939 has demonstrated strong antiproliferative activity against various human cancer cell lines, especially hematopoietic cancers, with IC₅₀ values in the nanomolar range [4] Group 2: Mechanism of Action - AB8939 acts as a microtubule destabilizer by binding to the colchicine-binding site on β-tubulin, leading to cell cycle arrest and apoptosis [4] - It also inhibits ALDH1 and ALDH2, which are often overexpressed in tumors and associated with cancer stem cells and therapy resistance [4] - The drug can overcome major mechanisms of drug resistance, such as P-glycoprotein (P-gp) efflux and high β3-tubulin expression, allowing it to remain effective in resistant cancer cells [4] Group 3: Clinical Trials - AB8939 is currently being evaluated in a Phase I/II clinical trial (AB18001) for patients with refractory and relapsed AML, with regulatory approval received to initiate the third stage of the study [5][6] - The first two stages of the trial involved 28 and 13 patients, respectively, determining the maximum tolerated dose (MTD) of 21.3 mg/m² after both three and fourteen consecutive days of treatment [6] Group 4: Intellectual Property and Regulatory Status - AB Science retains full ownership of the intellectual property rights for AB8939, with protection extending until 2036 or even 2044 for specific uses [7][9] - The drug has received orphan drug designation from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), granting marketing exclusivity for 10 years in Europe and 7 years in the US [10] Group 5: Preclinical Evidence - In preclinical models, AB8939 has shown significant inhibition of tumor growth and increased survival rates in Ara-C-resistant AML mouse models [12] - The drug effectively eradicated leukemic stem cells in patient-derived xenograft models, suggesting its potential to reduce the risk of disease relapse [12]

Core Insights - AB Science announced a new publication on MedRxiv detailing the clinical benefits of masitinib for amyotrophic lateral sclerosis (ALS) patients before any complete loss of function [2][3] Group 1: Study Findings - The post-hoc subgroup analysis from the phase 2b/3 AB10015 study shows significant improvement in functional decline measured by the ALSFRS-R score, with a 4.04-point difference favoring masitinib over placebo (p=0.0065) [4][5] - A relative benefit of +20.2% on the CAFS score was observed compared to placebo (p=0.0290), surpassing the +13.8% benefit seen in the primary analysis [5] - Median progression-free survival (PFS) was extended by 9 months (p=0.0057) and median overall survival (OS) increased by 12 months (p=0.0192) compared to placebo, both improvements being more pronounced than those in the primary analysis [5] Group 2: Safety and Patient Population - Safety outcomes improved, with a reduction in serious adverse events from 27.6% to 22.6% in masitinib-treated patients [5] - The subgroup analyzed included patients with a score of at least 1 on all ALSFRS-R items at baseline, representing approximately 85% of the primary analysis population [3][5] Group 3: Future Studies - The findings from this analysis will inform the design of the confirmatory study AB23005, which targets patients prior to any complete loss of function to optimize the benefit-risk balance [2][3] - Study AB23005 is a prospective, multicenter, randomized, double-blind, placebo-controlled trial involving 408 ALS patients, aiming to confirm the efficacy and safety of masitinib [7][8]

Core Viewpoint - AB Science has successfully completed a private placement raising EUR 2.8 million to finance the clinical development of its drug candidate AB8939 for acute myeloid leukemia (AML) [2][4]. Use of Proceeds - The net proceeds from the private placement will primarily be used to complete phase 1 of the AB8939 program and to initiate an expansion study involving approximately 15 AML patients [4][5]. Financial Impact - The private placement strengthens the company's cash position, allowing it to meet its financing needs for 2025 and beyond [5]. Private Placement Details - The private placement involved the issuance of 2,477,877 new ordinary shares, each accompanied by a share warrant (BSA), without preferential subscription rights [6][7]. - The issue price of one ABSA is set at EUR 1.13, reflecting a 24.99% discount to the volume-weighted average price over the preceding three trading days [8][9]. Shareholding Structure - Post-private placement, the company's total share capital will amount to EUR 729,474.72, consisting of 66,184,793 ordinary shares, with potential dilution from the exercise of BSAs [13][15]. Trading Information - The new shares are expected to be admitted to trading on Euronext Paris on October 22, 2025, and will be assimilated to existing shares [18]. Company Overview - AB Science specializes in the research, development, and commercialization of protein kinase inhibitors, targeting diseases with high unmet medical needs [25]. - The lead compound, masitinib, is already registered for veterinary use and is being developed for human medicine across various disease areas [25]. Drug Candidate Information - AB8939 is a synthetic microtubule-destabilizing drug candidate with broad anticancer activity, showing potential to overcome drug resistance commonly seen in chemotherapy [24].